Alexion Pharmaceuticals has synthesized new macrocycle compounds acting as complement factor B inhibitors reported to be useful for the treatment of age-related macular degeneration, multiple sclerosis, rheumatoid arthritis, retinal degeneration, chronic obstructive pulmonary disease (COPD), paroxysmal nocturnal hemoglobinuria and cardiovascular disorders.